<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331393</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-686</org_study_id>
    <nct_id>NCT03331393</nct_id>
  </id_info>
  <brief_title>The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis</brief_title>
  <official_title>The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis: A Chart Review Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the value of Orencia in rapidly progressing
      Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients discontinuing treatment before completing 12 months of therapy</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time from treatment initiation to discontinuation</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of Healthcare Resource Utilization (HCRU)</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Disease Activity Score (DAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Health Assessment Questionnaire (HAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein Levels</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>C-reactive protein (CRP) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Erythrocyte sedimentation rate (ESR) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Erosions</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Measured by radiographic reports</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA patients treated with Abatacept</arm_group_label>
    <description>Treated with Abatacept as a first-line biologic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RA patients treated with TNFi</arm_group_label>
    <description>Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>RA patients treated with Abatacept</arm_group_label>
    <arm_group_label>RA patients treated with TNFi</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Rapidly-progressing RA patients initiating treatment with abatacept or TNFi at
        approximately 10 rheumatology practices across the US.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age at enrollment

          -  Confirmed diagnosed with RA

          -  Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab
             with a record of the start date at the practice site

        Exclusion Criteria:

          -  Does not have at least 1 or more poor RA prognostic factor: Evidence of joint
             erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP
             levels, Increased ESR levels

          -  Was followed at the site for less than 1 year since biologic treatment initiation

          -  Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative
             colitis, psoriatic arthritis, anal fistula

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

